Non-nucleoside reverse transcriptase inhibitors (NNRTIs) -
2D and 3D QSAR of Benzimidazole Analogues as Novel HIV-1 Non Nucleoside Reverse Transcriptase Inhibitors
7
Molecular modeling studies of HIV-1 non-nucleoside reverse transcriptase inhibitors using 3D-QSAR, virtual screening and docking simulations
14
Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
8
Comparative Study of Various Non-Nucleoside Reverse Transcriptase Inhibitors on Different Reverse Transcriptase Enzyme
7
AZOLES AS NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs): MINI REVIEW
6
Inhibitory activity of 9 phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV 1 as non nucleoside reverse transcriptase inhibitors
6
AN INSIGHT TO STRUCTURAL ANALYSIS OF COUMARINS AS NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
18
Increase in transmitted resistance to non nucleoside reverse transcriptase inhibitors among newly diagnosed HIV 1 infections in Europe
12
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
9
Synthesis, biological evaluation and docking study of 2 amino 4,6 diarylpyrimidines as novel non nucleoside HIV 1reverse transcriptase inhibitors
9
Benzophenone Derivatives: a Novel Scaffold as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
9
Impact of Y181C and/or H221Y mutation patterns of HIV 1 reverse transcriptase on phenotypic resistance to available non nucleoside and nucleoside inhibitors in China
7
Selective killing of human immunodeficiency virus infected cells by non nucleoside reverse transcriptase inhibitor induced activation of HIV protease
14
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors
18
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
14
Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non Nucleoside Inhibitors to HIV Reverse Transcriptase
16
Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors
13
Bench to bedside review: Severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors
7
Synthesis and docking analysis of new 2 chloro 3 ((2,2 dimethylhydrazono) methyl)quinoline derivatives as non nucleoside human HIV 1 reverse transcriptase inhibitors
6
R5 Variants of Human Immunodeficiency Virus Type 1 Preferentially Infect CD62L− CD4+ T Cells and Are Potentially Resistant to Nucleoside Reverse Transcriptase Inhibitors
12